Testing treprostinil plus riociguat for advanced pulmonary artery hypertension
Part of Lungs & breathing clinical trials.
This study tests whether taking injected treprostinil together with riociguat can improve how the heart and lung blood vessels work in people with advanced pulmonary artery hypertension (PAH). It may help improve blood-flow measurements and the structure of the heart.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have WHO Group 1 pulmonary artery hypertension (PAH).
- During a right heart catheter test, your mPAP is 25 mmHg or higher, and your wedge pressure is 15 mmHg or lower.
- Your PH (lung blood pressure) specialist feels you need injected treprostinil (treprostinil given by injection/infusion).
- Your blood pressure is strong enough (mean arterial pressure is at least 60) and you do not require blood-pressure support medicines.
- You are able to have the required right heart catheter study test (no known reason you can’t).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an inhaled medication (TPIP) that opens blood vessels in the lungs to help you breathe easier and be more active. It is for people with PAH who are already on stable treatment and have moderate symptoms.
This trial tests a medicine called treprostinil in children with severe pulmonary arterial hypertension (high blood pressure in the lungs). The study aims to see if it is safe and tolerable for kids who need this kind of therapy.
This study compares starting treatment with three medicines, including a continuous infusion (treprostinil), versus two oral medicines for people newly diagnosed with moderate-to-high risk pulmonary arterial hypertension (PAH). The goal is to see which approach improves heart function and symptoms more effectively.
This study is testing how safe and effective Remodulin is for people with severe pulmonary arterial hypertension (PAH). You will receive Remodulin as a continuous injection under the skin or into a vein, and the study will monitor your health to see how well it works.
This study tests an inhaled powder medication called TPIP (treprostinil palmitil inhalation powder) to see if it can improve symptoms and exercise ability in people who have both interstitial lung disease and pulmonary hypertension. The study will compare TPIP against a placebo (a dummy treatment without the active drug) to understand how well it works and if it is safe.
This study tests a new drug, tiprelestat, added to your current treatment for pulmonary arterial hypertension (PAH). It aims to see if it improves your symptoms and exercise ability.
Hear when a new Pulmonary Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.